drugset / Trial / NCT00467870

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

NCT00467870

Phase 3 Completed 531 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.

Timeline

Start
2006-03
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 750 mg Intramuscular
Subject Testosterone Undecanoate Small molecule 1000 mg Intramuscular

Indications